India, Sept. 3 -- A few days ago, this newspaper quoted an Indian trade expert who predicted that the US may impose up to 200 per cent tariff on Indian pharmaceutical exports within a few months. The business prophecy is turning out to be true sooner than later. News is filtering through that the Donald Trump administration has proposed the same duty on some imported drugs under Section 232 of the Trade Expansion Act of 1962. Although Indian pharma is exempt from the existing 50 per cent tariff, this newspaper had argued that a higher duty regime was in the offing due to the ongoing investigation under this section. While this may sound like a death knell for the Indian industry, it is a double-edged sword. It can yield super profits in t...